NCT05767359View on ClinicalTrials.gov

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 19, 2023

Primary Completion Date

January 15, 2026

Study Completion Date

January 15, 2040

Conditions
Multiple MyelomaSmoldering Multiple Myeloma
Interventions
DRUG

Ciltacabtagene Autoleucel

Genetically modified autologous T-cell immunotherapy, via intravenous infusion per protocol.

DRUG

Cyclophosphamide

Lymphodepleting conditioning regimen, nitrogen mustard-derivative, via intravenous infusion per standard care.

DRUG

Fludarabine Phosphate

Lymphodepleting conditioning regimen, synthetic purine nucleoside, via intravenous infusion per standard care.

Trial Locations (1)

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER